nach oben

Erschienen in:

01.01.2008 | Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk

verfasst von: Claire E. Wakefield, Bettina Meiser, Judi Homewood, Michelle Peate, Alan Taylor, Elizabeth Lobb, Judy Kirk, Mary-Anne Young, Rachel Williams, Tracy Dudding, Kathy Tucker, the AGenDA Collaborative Group

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To measure the effectiveness of a tailored decision aid (DA) designed to help women make informed decisions about genetic testing for breast/ovarian cancer risk.

Methods

A total of 145 women were randomized to receive the DA or a control pamphlet at the end of their first genetic counseling consultation. Of these, 120 (82.8%) completed two questionnaires, 1 week and 6 months post-consultation.

Results

While the DA had no effect on informed choice, post-decisional regret or actual genetic testing decision, the trial showed that women who received the DA had higher knowledge levels and felt more informed about genetic testing than women who received the control pamphlet (χ²(2) = 6.82; P = 0.033; χ²(1) = 4.86; P = 0.028 respectively). The DA also helped women who did not have blood drawn at their first consultation to clarify their values with regards to genetic testing (χ²(1) = 5.27; P = 0.022). Women who received the DA were less likely to share the information with other family members than women in the control condition (χ²(1) = 8.78; P = 0.003).

Conclusions

Decision aids are an effective decision-support strategy for women considering genetic testing for breast/ovarian cancer risk, and are most effective before the patient has made a decision, which is generally at the point of having blood drawn.

International Breast Cancer Intervention Study Investigators (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824

Hartmann LC, Schaid DJ, Woods JE et al (1999) Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77–84PubMedCrossRef

Scheuer L, Kauff N, Robson M et al (2002) Outcome and preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20:1260–1268PubMedCrossRef

Meijers-Heijboer H, Van Geel B, Van Putten W et al (2001) Breast cancer after prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345:159–164PubMedCrossRef

Levy-Lahad E, Friedman E (2007) Cancer risks among BRCA1 and BRCA2 mutation carriers. BJC 96:11–15PubMed

Lodder LN, Frets PG, Trijsburg RW et al (2002) One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73:97–112PubMedCrossRef

Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676–689PubMedCrossRef

National Health and Medical Research Council (1999) Familial aspects of cancer: A guide to clinical practice. National Health and Medical Research Council, Canberra, November 1999

Meiser B (2005) Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 14:1060–1074PubMedCrossRef

10.

van Dijk S, Otten W, Timmermans DR et al (2005) What’s the message? Interpretation of an uninformative BRCA1/2 test result for women at risk of familial breast cancer. Genet Med 7:239–245PubMedCrossRef

11.

van Dijk S, Timmermans DRM, Meijers-Heijboer H et al (2006) Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer. J Clin Oncol 24:3672–3677PubMedCrossRef

12.

Ropka M, Wenzel J, Phillips E et al (2006) Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev 15:840–855PubMedCrossRef

13.

O’Connor AM, Mulley AG Jr, Wennberg JE (2003) Standard consultations are not enough to ensure decision quality regarding preference-sensitive options. J Natl Cancer Inst 95:570–571PubMedCrossRef

14.

O’Connor AM, Rostom A, Fiset V et al (1999) Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 319:731–734PubMed

15.

O’Connor A, Tugwell P, Welles GA et al (1998) Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventative hormone replacement therapy. Med Decis Making 18:295–303PubMedCrossRef

16.

O’Connor AM (1999) Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst 25:67–80

17.

Elwyn G, O’Connor A, Stacey D et al (2006) Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 333:417PubMedCrossRef

18.

Wakefield CE, Meiser B, Homewood J et al (in press) Development and pilot testing of two decision aids for individuals considering genetic testing for cancer risk. J Genet Couns

19.

Australian Cancer Network (1999) Guidelines on familial aspects of cancer. Australian Cancer Network, Sydney, November 1999

20.

National Breast Cancer Centre (2000) Current best advice about familial aspects of breast/ovarian cancer. NHMRC National Breast Cancer Centre, Sydney, 2000

21.

Centre for Genetics Education (2007) Centre for Genetics Education. http://www.genetics.com.au/. Cited 19 Jan 2007

22.

O’Connor AM, Stacey D, Entwistle V et al (2006) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 1:1

23.

Rimer BK, Glassman B (1999) Is there a use for tailored print communications in cancer risk communication? J Natl Cancer Inst 25:140–148

24.

Bastani R, Maxwell A, Bradford C et al (1999) Tailored risk notification for women with a family history of breast cancer. Prev Med 29:355–364PubMedCrossRef

25.

O’Connor AM (1995) Validation of a decisional conflict scale. Med Decis Making 15:25–30PubMedCrossRef

26.

Michie S, Dormandy E, Marteau TM (2002) The multi-dimensional measure of informed choice: a validation study. Patient Educ Couns 48:87–91PubMedCrossRef

27.

Horowitz MJ, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41:209–218PubMed

28.

Thewes B, Meiser B, Hickie IB et al (2001) Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psychooncology 10:459–468PubMedCrossRef

29.

Zigmond A, Snaith R (1983) The hospital anxiety and depression scale. Psychiatr Scand 67:361CrossRef

30.

Hall A, A’Hern R, Fallowfield L (1999) Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer? Eur J Cancer 35:79–85PubMedCrossRef

31.

Johnston M, Pollard B, Hennessey P (2000) Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res 48:579–584PubMedCrossRef

32.

Ibbotson T, Maguire P, Selby P et al (1994) Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 30A:37–40PubMedCrossRef

33.

Brehaut JC, O’Connor AM, Wood TJ et al (2003) Validation of a decision regret scale. Med Decis Making 23:281–292PubMedCrossRef

34.

SPSS Inc. (2005) Statistical Program for the Social Sciences: Release 14.0. SPSS Inc., Chicago, IL

35.

StataCorp (2005) Stata Statistical software: Release 9.0. StataCorp, College Station, TX

36.

Williams RL (2000) A note on robust variance estimation for cluster-correlated data. Biometrics 56:645–646PubMedCrossRef

37.

Bekker HL, Legare F, Stacey D et al (2003) Is anxiety a suitable measure of decision aid effectiveness: a systematic review? Patient Educ Couns 50:255–262PubMedCrossRef

38.

Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118:201–209PubMedCrossRef

39.

Cull A, Anderson EDC, Campbell S et al (1999) The impact of genetic counselling about breast cancer risk on women’s risk perceptions and levels of distress. BJC 79:501–508PubMed

40.

Lerman C, Narod S, Schulman K et al (1996) BRCA1 testing in families with hereditary breast-ovarian cancer. JAMA 275:1885–1892PubMedCrossRef

41.

Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT et al (2000) Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 335:2015–2020CrossRef

42.

O’Neill SM, Peters JA, Vogel VG et al (2006) Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet C 142:221–231

43.

Mancini J, Nogues C, Adenis C et al (2006) Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer 42:871–881PubMedCrossRef

44.

Mireskandari S, Meiser B, Sherman K et al (2006) Evaluation of the needs and concerns of partners of women at high risk of developing breast/ovarian cancer. Psychooncology 15:96–108PubMedCrossRef

45.

Manne S, Audrain J, Schwartz M et al (2004) Associations between relationship support and psychological reactions of participants and partners to BRCA1 and BRCA2 testing in a clinic-based sample. Ann Behav Med 28:211–225PubMedCrossRef

46.

Schwartz MD, Lerman C, Brogan B et al (2005) Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 14:1003–1007PubMedCrossRef

47.

Australian Bureau of Statistics (2006) Australian social trends 2006. Australian Bureau of Statistics, Canberra

48.

Meiser B, Butow P, Friedlander M et al (2002) Psychological impact of genetic testing for women for breast cancer susceptibility. Eur J Cancer 38:2025–2033PubMed

49.

Tiller K, Meiser B, Gaff C et al (2006) A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Med Decis Making 26:360–372PubMedCrossRef

Titel: A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk
verfasst von: Claire E. Wakefield
Bettina Meiser
Judi Homewood
Michelle Peate
Alan Taylor
Elizabeth Lobb
Judy Kirk
Mary-Anne Young
Rachel Williams
Tracy Dudding
Kathy Tucker
the AGenDA Collaborative Group
Publikationsdatum: 01.01.2008
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9539-2

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk